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A B S T R A C T
Background: Exposure to diisocyanates is an important cause of occupational asthma (OA) in the industrialized
world. Since OA occurs after long-term exposure to diisocyanates, we developed a chronic mouse model of
chemical-induced asthma where toluene diisocyanate (TDI) was administered at two different exposure sites.
Objectives: Evaluating the effect of long-term respiratory isocyanate exposure - with or without prior dermal
exposure- on sensitization, inflammatory responses and airway hyperreactivity (AHR).
Methods: On days 1 and 8, BALB/c mice were dermally treated (20 μl/ear) with 0.5% 2,4-toluene diisocyanate
TDI or the vehicle acetone olive oil (AOO) (3:2). Starting from day 15, mice received intranasal instillations with
0.1% TDI of vehicle five times in a week, for five successive weeks. One day after the last instillation airway
hyperreactivity (AHR) to methacholine was assessed, followed by an evaluation of pulmonary inflammation and
structural lung changes. Immune-related parameters were assessed in the lungs (BAL and tissue), blood, cervical-
and auricular lymph nodes.
Results: Mice repeatedly intranasally exposed to TDI showed systemic sensitization and a mixed Th1/Th2 type
immune response, without the presence of AHR. However, when mice are first dermally sensitized with TDI,
followed by repeated intranasal TDI challenges, this results in a pronounced Th2 response and AHR.
Conclusion: Dermal exposure to TDI determines airway hyperreactivity after repeated airway exposure to TDI.
1. Introduction
Exposure to diisocyanates is an important cause of occupational
asthma (OA) (Maestrelli et al., 2009). Diisocyanates are low molecular
weight (LMW) compounds, used in spray foam insulation, plastic
packaging and paints. They may act as haptens and bind with self-
proteins to form functional antigens recognized by the immune system
(Hettick and Siegel, 2011; Wisnewski and Liu, 2013). To date, a
growing number of animal and workplace observational studies suggest
that skin exposure to isocyanates elicits immune sensitization. After
sensitization, very low airway exposures, can induce asthma (Tarlo,
2003; Bello et al., 2007; Redlich and Herrick, 2008; Wisnewski et al.,
2011). Therefore, the American Conference of Governmental Industrial
Hygienist lowered the threshold limit value time-weighted average
(TLV-TWA) from 5 ppb to 1 ppb (ACGIH, 2016). However, Lynch et al
(2018) criticized the basis for lowering the TLV (Lynch et al., 2018).
The incidence of diisocyanate-induced-asthma varies from 6.1/100
person years (Jaakkola et al., 2013) to 9/100 person years (Collins
et al., 2017). Yet, the incidence of allergic skin disease induced by
diisocyanates is not well investigated.
Sub-chronic and chronic pulmonary exposure to diisocyanates has
been studied before in rat and mouse to mimic human asthma
(Scheerens et al., 1999; Matheson et al., 2005b; Ban et al., 2006; Lee
et al., 2011). While adaptive immune responses have been investigated
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in diisocyanate asthma, little is known about the involvement of den-
dritic cells (DC) in this type of asthma (Matheson et al., 2005a). DC are
the most important antigen presenting cells (APC) responsible for in-
itiating an immune response. They are located near the epithelium,
where they can sense and capture inhaled antigens present in the en-
vironment. After collecting, DC process the allergens into small pep-
tides and migrate to the T cell zone of the local draining lymph nodes.
There they present the processed antigens via the major histocompat-
ibility complexes (MHC class I and II) to naive T cells, inducing po-
larized T-cells (Holgate, 2012; van Helden and Lambrecht, 2013). In
total, three distinct DC subsets are defined in the lung each with their
own surface markers and functional specialization: conventional DC
(cDC), which can be further divided in CD11b+ and CD103+ cDC,
plasmacytoid DC (pDC) and monocyte derived DC (moDC) (Plantinga
et al., 2013). Each of those DC subsets are geared to induce a particular
helper T cell response. These responses are context dependent: en-
vironmental signals (house dust mite, cigarette smoke, diesel exhaust
particles etc…), dose, routes of exposures and cell-released molecular
patterns influence the function of DC which emphasize the plasticity of
DC (Willart and Lambrecht, 2009; Provoost et al., 2010; Plantinga et al.,
2013; Kopf et al., 2015).
In this manuscript, we investigated the importance of exposure
route (dermal/respiratory) on adaptive immunity, lung inflammatory
responses and AHR in a chronic mouse model consisting of long-term
nasal mucosa exposure, with or without a brief prior skin exposure.
2. Methods
2.1. Reagents
Toluene-2,4-diisocyanate (TDI) (98%, CAS584-84-9), acetyl-β-me-
thylcholine (methacholine) and acetone were obtained from Sigma-
Aldrich (Bornem, Belgium). Pentobarbital (Nembutal®) was obtained
from the internal animal facility at the University of Leuven. The ve-
hicle acetone olive oil (AOO) used to dissolve TDI consists of a mixture
of 2 volumes acetone and 3 volumes of olive oil (highly refined, low
acidity, CAS8001-25-0) obtained from Sigma Aldrich. Concentration of
TDI is given as percentage (v/v) in AOO.
2.2. Mice
Male BALB/c mice (6–8 weeks old) were obtained from the internal
stock of the animalium (University of Leuven, Belgium). All mice were
housed in a conventional animal house with 12 h dark/light cycles, in
filter top cages. They received lightly acidified water and pelleted food
ad libitum. All experimental procedures were approved by the local
Ethical Committee for animal experiments (P063/2015).
2.3. Experimental protocols of mouse experiments
On days 1 and 8, mice received dermal applications of 20 μl of 0.5%
TDI or the vehicle AOO. From day 15, mice received, under light iso-
flurane anesthesia, intranasal instillations (40 μl) of 0.1% TDI or the
vehicle AOO, 5 times a week for 5 consecutive weeks. All experimental
groups are indicated with two abbreviations: the first abbreviation in-
dicates the dermal treatment on days 1 and 8, whereas the second
abbreviation indicates the intranasal instillations. The AOO/AOO group
never received TDI, the AOO/TDI group only received intranasal TDI
and the TDI/TDI group received TDI dermally and intranasally.
2.4. Analysis in different sets of experiments
In this study we have three different sets of experiments. In the first
set we evaluated the AHR and histological changes in the lung, IgE and
IgG in blood serum, IgE and inflammation in BAL and T and B cells with
in vitro cytokine secretion of the auricular and cervical lymph nodes
(n= 6–7/group). To increase the number of the auricular and cervical
lymph nodes, we included a second set where we evaluated the T and B-
cells with in vitro cytokine secretion of the auricular and cervical lymph
nodes (n= 4–6/group). To analyze the DC, we included a third set. In
the latter set we analyzed IgE in blood serum (to confirm sensitization),
inflammation in BAL and DC, T and B cells in lung cells (n= 8/group).
In a subgroup of this set we also evaluated the T and B cells in the
auricular and cervical lymph nodes (n=4/group).
2.5. Airway and lung tissue hyperreactivity measurements
Twenty-four hours after the last instillation, airway and lung tissue
reactivity to methacholine was measured using a forced oscillation tech-
nique (FlexiVent 7.1, SCIREQ, Montreal, Canada). Mice were anesthetized
with pentobarbital (70mg/kg body weight, Nembutal®). Applying the
‘quick prime 3′(QP3) perturbation, airway resistance (Rn), and tissue
elasticity (H) to increasing concentrations of methacholine (0, 1.25, 2.5, 5,
10, 20mg/ml) was measured. After each concentration, the QP3 pertur-
bation was performed 5 times spread over 2min. If the COD (Coefficient of
Determination) of a QP3 perturbation was lower than 0.90, the mea-
surement was excluded and not used to calculate the average. For each
mouse Rn and H were plotted against methacholine concentration and the
area under the curve (AUC) was calculated to perform statistical analysis.
2.6. Lung, lymph node and serum analysis
2.6.1. Serum sampling
After measuring airway hyperreactivity to methacholine, mice were
sacrificed. Blood was sampled from the retro-orbital plexus, centrifuged
(14,000 g, 4 °C, 10min) and serum samples were stored at −80 °C until
analysis.
2.6.2. Broncho-alveolar lavage (BAL)
The lungs were lavaged, in situ, three times with 0.7 ml sterile saline
(0.9% NaCl), and the recovered fluid was pooled. Cells were counted
using a Bürker hemocytometer (total cell count) and the BAL fluid was
centrifuged (1000 g, 10min). For differential cell counts, 250 μl of the
resuspended cells (100,000 cells/ml) were spun (300 g, 6min)
(Cytospin 3, Shandon, TechGen, Zellik, Belgium) onto microscope
slides, air-dried and stained (Diff-Quik® method, Medical Diagnostics,
Düdingen, Germany). For each sample, 200 cells were counted for the
number of macrophages, eosinophils, neutrophils.
2.6.3. Single cell suspension
The pulmonary circulation was rinsed with saline/EDTA to remove
the intravascular pool of cells. A cell suspension of the lungs was ob-
tained using digestion medium (RPMI 1640 supplemented with 5%
FCS, 2mM L-glutamine, 0.05mM 2-mercaptoethanol [Gibco;
Invitrogen, Paisley, United Kingdom], 100 U/mL penicillin–100mg/ml
streptomycin [Invitrogen], 1 mg/ml collagenase type 2 [Worthington
Biochemical, Lakewood, NY], and 0.02mg/ml DNase I [grade II from
bovine pancreas; Boehringer Ingelheim, Ingelheim, Germany]) for
45min at 37 °C and 5% CO2. Red blood cells were lysed by using am-
monium chloride buffer. Cells were counted using a Bürker hemocyt-
ometer and resuspended (107 cells/ml) in PBS.
The left and right retro-auricular as well as the two cervical lymph
nodes from the same mice were pooled and kept on ice in RPMI-1640 (1X)
+ GlutaMAX™-I (Invitrogen, Merelbeke, Belgium). Cell suspensions were
obtained by pressing the lymph nodes through a cell strainer (100 μm) (BD
Bioscience, Erembodegem, Belgium) and rinsing with 10ml tissue culture
medium (RPMI-1640 (1X) + GlutaMAX™-I). After centrifugation (1000 g,
10min), cells were counted using a Bürker hemocytometer and re-
suspended (107 cells/ml) in complete tissue culture medium (RPMI-1640
(1X) + GlutaMAX™-I supplemented with 10% heat-inactivated fetal bovine
serum, 10mg/ml streptomycin/penicillin).
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2.6.4. Flow cytometry
2.6.4.1. T- and B cells. Five-hundred thousand cells from the auricular/
cervical lymph nodes and lung were stained with anti-CD3+ (APC),
anti-CD4+ (APC-Cy7), anti-CD8+ (PerCP-Cy5.5) and anti-CD25+ (PE),
or received a single staining with anti-CD19+ (PE) labeled antibodies,
according to standard procedures (BD Biosciences, Erembodegem,
Belgium). Percentages of labeled cells were determined by performing
flow cytometry (FACSArray, BD Biosciences, Erembodegem, Belgium)
on at least 105 cells.
2.6.4.2. Dendritic cells. To minimize nonspecific bindings, two million
cells of lung and auricular lymph nodes, were preincubated with anti-
CD16/CD32 (Clone 2.4G2) (from BD Biosciences, San Jose, Calif). After
live/dead staining using the Zombie Aqua™ Fixable Viability Kit, cells
were labeled with combinations of anti-mouse fluorochrome-
conjugated mAbs against CD45 (clone 30-F11), CD11c (N418), MHCII
(M5/114.15.2), CD11b (M1/70), CD103 (2E7), CD64 (X54-5/7.1),
Siglec-H (551) (all from Biolegend, San Diego, Calif). Data acquisition
was performed on a LSR Fortessa flow cytometer running DIVA
software (BD Biosciences, San Jose, Calif). FlowJo software (TreeStar,
Inc, Ashland, Ore) was used for data analysis. We composed our DC
panel based on those of Provoost et al. and Plantinga et al. (Provoost
et al., 2010, 2012; Plantinga et al., 2013)
2.6.4.3. Cytometric bead array. Cells of the auricular and cervical
lymph nodes were seeded into 48-well culture plates at a density of
106 cells/ml and incubated in complete RPMI-1640 (1X) +
GlutaMAX™-I medium for 42 h with 2.5 μg/ml of concanavalin A
(ConA) (Sigma–Aldrich, Bornem, Belgium). Cell suspension were
centrifuged (1000 g, 10min) and supernatant was stored at −80 °C.
Concentrations of interleukin-4 (IL-4), IL-10, IL-13 and interferon
gamma (IFN-γ) were measured via the LSR Fortessa (BD Biosciences,
Erembodegem, Belgium). Detection limits were 0.2 pg/ml, 0.3 pg/ml,
9.6 pg/ml, 2.4 pg/ml and 0.5 pg/ml, respectively.
2.6.5. Enzyme-linked immuno sorbent assay (ELISA)
The OptEIA Mouse IgE set from pharmingen (BD Biosciences) was used
to measure total IgE in serum (diluted 1/70 for AOO/AOO and 1/1000 for
the AOO/TDI and TDI/TDI treated group) and BAL (undiluted).
Measurements were performed according to the manufacturer’s instruc-
tions. To measure total serum IgG1 (diluted 1/8000 or 1/106) an IgG2a
(diluted 1/4000) plates were coated using purified rat anti-mouse IgG1 (Cat:
553445, BD PharmingenTM) and purified rat anti-mouse IgG2a (Cat:
553446, BD PharmingenTM). A standard was created using purified mouse
IgG1 (Cat: 557273, BD PharmingenTM) and purified Mouse IgG2a (Cat:
553454, BD PharmingenTM). The further measurements were preformed
according to the manufacturer's (BD Pharmingen) instructions with the use
of biotinylated anti-mouse avidin horseradish peroxidase conjugate (HRP
rat anti-mouse IgG1, Cat:559626, biotin rat anti-mouse IgG2a, Cat: 553388,
and streptavidin HRP, Cat: 554066, BD PharmingenTM).
The Quantikine mouse IL-13 ELISA from R&D systems (Abingdon,
UK) was used to measure IL-13 levels in serum. The ELISA was
Fig. 1. Leukocytes and dendritic cells ALN. Cells
were analyzed, using a flow cytometer.
Leukocytes were assessed as CD45+ cells (a). DC
were detected as low auto fluorescent
MHCII+CD11c+ DC (b). Fig. 1c demonstrates the
parent % of CD45+ low auto fluorescent
MHCII+CD11c+CD11b−CD103+ cDC (CD103+
cDC), CD45+ low auto fluorescent
MHCII+CD11c+CD11b+CD103− conventional
DC (CD11b+ cDC), CD45+ low auto fluorescent
MHCII+CD11c+CD11b+CD64+ monocyte de-
rived DC (moDC), and CD45+ low auto fluor-
escent MHCII+CD11c+ SiglecH+ plasmacytoid
DC (pDC). Experimental groups are identified by
two abbreviations (AOO=acetone olive oil;
TDI= toluene-2,4-diisocyanate); the first ab-
breviation indicates the dermal treatment on days
1 and 8, whereas the second abbreviation in-
dicates the intranasal instillations. n=8 per
group. Bars shows the mean with SD. **p < 0.01
and ***p < 0.001 compared with the AOO/
AOO control group.
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performed according to the manufacturer’s instructions, using un-
diluted serum samples. The detection limit was 1.5 pg/mL.
2.6.6. Histology
Lungs were instilled with 4% formaldehyde until full inflation of all
lobes. Evaluation of lung injury on slides stained by hematoxylin and eosin
(H&E) was performed by an experienced pathologist in a blinded manner.
Inflammation (i.e., infiltration of macrophages/monocytes or leukocytes),
epithelial damage (i.e., disruption of the epithelial barrier in the airways)
and alveolar widening (airspace enlargements) were scored on semi-quan-
titative scale of 0–4 (0 is no changes; 1 is minor changes; 2 is moderate
changes; 3 is substantial changes; and 4 is severe changes).
2.7. Data analyses
The data are presented as means with standard deviation (SD), or as
individual mice and group mean. Normality of distribution was as-
sessed by the Kolmogorov-Smirnov test, followed by a one-way para-
metric ANOVA combined with a bonferroni multiple comparison post
hoc test. Dose–response curves (AHR) were analysed using two-way
parametric ANOVA, followed by a Bonferroni multiple comparison post
hoc test (Graph Pad Prism 5.01. Graphpad Software Inc, San Diego,
USA). A level of p < 0.05 (two tailed) was considered significant.
3. Results
3.1. Markers of sensitization
3.1.1. Dendritic cells in auricular lymph nodes
Fig. 1b and c shows a significant increase of DC, CD11b+ cDC in
both TDI-treated groups TDI (AOO/TDI and TDI/TDI) compared to the
control group (AOO/AOO). There seems to be an increasing trend of
moDC and a decreasing trend of CD103+ cDC and pDC in both TDI-
treated groups, yet significance is not reached (Fig. 1c). Total number of
leukocytes were not significant increased (Fig. 1a).
3.1.2. T- and B cells in auricular and cervical lymph nodes
Fig. 2a shows that mice, treated with TDI (AOO/TDI and TDI/TDI),
have significantly more T-(CD3+) and B-(CD19+) cells in the auricular
lymph nodes than the AOO/AOO control group. More specifically, all T-
cell subpopulations (CD4+ T-helper, CD4+CD25+ activated/regulatory
T-cells and CD8+ cytotoxic T-cells) were significantly increased in both
TDI-treated groups. In the cervical lymph nodes (Fig. 2b), CD19+ B-
cells were increased in TDI/TDI treated group while CD8+ cytotoxic T-
cells were only increased in the AOO/TDI treated group (Fig. 2b).
3.1.3. Ex vivo cytokine secretion
Ex vivo stimulation of auricular lymphocytes with concanavalin A
had in significantly increased concentrations of IL-4, IL-10, IL-13 and
IFN-γ in the TDI/TDI treated group, compared to the control group
(AOO/AOO) (Fig. 3a–d). IL-4, IL-10 and IL-13 concentrations in the
cultured auricular lymphocytes of the TDI/TDI group were also sig-
nificantly higher compared to the non-sensitized, and only TDI chal-
lenged group (AOO/TDI) (Fig. 3a–c). The AOO/TDI treated group
showed a significant increase in IL-13 and IFN-γ compared to the
control group (AOO/AOO) (Fig. 3b and d). The ex vivo cytokine pro-
duction of the cervical lymphocytes was substantially lower than in the
auricular lymph nodes (Fig. 3e–h). In the TDI/TDI treated group in-
creased concentrations of IL-4, IL-13 and IL-10 were found, while in the
AOO/TDI treated group only IL-13 was significantly increased com-
pared to the control group (AOO/AOO) (Fig. 3e–g). The IFN-γ levels
were not significantly changed (Fig. 3h).
3.1.4. Immunoglobulines and serum IL-13
Fig. 4a shows that mice, which received weekly intranasal instillations
with TDI (AOO/TDI), resulted in a significant increase of total serum IgE
compared to the control group (AOO/AOO). However, TDI skin exposure
followed by TDI-intranasal instillations (TDI/TDI) resulted in a significantly
higher concentration of IgE in serum compared to the TDI challenged and
control groups (AOO/TDI and AOO/AOO) (Fig. 4a). Besides the serum, IgE
was also significant increased in the BAL fluid of the TDI/TDI group
(Fig. 4d). Serum IgG1 was significantly increased and IgG2a was significantly
decreased in the TDI/TDI group, compared to the control group (AOO/
AOO) (Fig. 4b and c). IL-13 in serum showed a significant increase in both
TDI treated groups (AOO/TDI and TDI/TDI) compared to the control group
(AOO/AOO). Moreover, the IL-13 level in the TDI/TDI group is significantly
higher compared to AOO/TDI group (Fig. 4e).
3.2. Airway response
3.2.1. Airway hyperreactivity
Fig. 5a and c, shows the dose-response increase of methacholine-
induced airway resistance (Rn) and tissue elasticity (H), while Fig. 5b
and d show the area under the curve of the individual mice and the
group average. Airway hyperreactivity (AHR) in the TDI/TDI group is
significant increased compared to both other groups (AOO/TDI and
AOO/AOO).
3.2.2. Broncho-alveolar lavage and lung histology
The AHR in TDI/TDI treated group was not accompanied by in-
creases in inflammatory cells (neutrophils, eosinophils or lymphocytes)
in BAL fluid, where only macrophages were present (mean +/- SD:
AOO/AOO 7.5 +/- 3.9 (x104); AOO/TDI 5.3 +/- 4.2 (x104); TDI/TDI
5.9 +/- 2.4 (x104)). Histological analysis revealed that long-term in-
tranasal exposure to TDI resulted in limited increased inflammation
round the blood vessels, characterized by macrophages/monocytes and
leucocytes, epithelial shedding, with limited disruption of the epithelial
barrier in the airways of mice challenged with TDI and alveolar
widening, characterized by airspace enlargements. Yet, none of the
semi-quantitatively judged parameters are significantly different
(Fig. 6a–c)).
3.2.3. T- and B cells in the lung
Table 1 shows a significant increase in CD3+D8+ cytotoxic T cells
in the TDI/TDI treated group compared to the AOO/AOO group. No
statistical differences were found in CD3+ T helper cells of the TDI-
treated groups (AOO/TDI and TDI/TDI), compared to the control group
(AOO/AOO).
3.2.4. Dendritic cells in the lung
Only the moDC subpopulation in the lung from the TDI/TDI treated
group are significantly higher than the control group (AOO/AOO) (Table 2).
There were no significant differences in total number of leukocytes, den-
dritic cells, nor in the DC subpopulations: 103+cDC, CD11b+cDC, pDC and
macrophages between the different treatment groups.
4. Discussion
Many efforts have been done to elucidate the mechanisms of che-
mical-induced asthma. Most of the work is performed in acute mouse
models of chemical-induced asthma, with limited numbers of airway
exposures (Vanoirbeek et al., 2004, 2008; Tarkowski et al., 2007; Lee
et al., 2011; De Vooght et al., 2013; Pauluhn, 2014; Devos et al., 2015,
2016; Cruz et al., 2016; Pollaris et al., 2016). However, it takes weeks
to years before initial onset of work-related asthma symptoms occurs.
Here, we show that TDI skin exposure in combination with repeated
five-week TDI airway exposure results in a pronounced Th2 hy-
persensitivity and AHR, while mice only exposed via the nasal mucosa
to TDI, without prior dermal contact, showed a more Th1/Th2 systemic
response without airway hyperreactivity.
TDI is able to migrate from the skin to the T-cell rich area of the
cortex in the dermal lymph nodes (Nayak et al., 2014). This suggests
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Fig. 2. Lymphocyte subpopulations in auri-
cular and cervical lymph nodes. Lymphocyte
subpopulations in ALN (a) and CLN (b) were
measured using flow cytometry. Lymphocytes
were stained with anti-CD3+ (T lymphocytes),
anti-CD3+CD4+ (Th-lymphocytes), anti-
CD3+CD4+CD25+ (activated/regulatory Th-
lymphocytes) and anti-CD3+CD8+ (Tc-lym-
phocytes) or stained with a single anti-CD19+
(B-lymphocytes). Experimental groups are
identified by two abbreviations
(AOO=acetone olive oil; TDI= toluene-2,4-
diisocyanate); the first abbreviation indicates
the dermal treatment on days 1 and 8, whereas
the second abbreviation indicates the in-
tranasal instillations. n= 14 per group. Bars
show the mean with SD. **p < 0.01 and
***p < 0.001 compared with the AOO/AOO
control group. #p < 0.05 compared to the
AOO/TDI treated group.
Fig. 3. Ex vivo cytokine production by auri-
cular (a–d) and cervical (e–h) lymphocytes.
Levels of IL-4 (a, e), IL-13 (b, f), IL-10 (c, g)
and IFN-γ (d, h) were measured by Cytometric
Bead Array in supernatant of auricular and
cervical lymphocytes. Experimental groups are
identified by two abbreviations
(AOO=acetone olive oil; TDI= toluene-2,4-
diisocyanate); the first abbreviation indicates
the dermal treatment on days 1 and 8, whereas
the second abbreviation indicates the in-
tranasal instillations. n=10–11 per group for
the ALN, and 6–10 for the CLN. Bars show the
mean and SD. *p < 0.05, **p < 0.01 and
***p < 0.001 compared with the AOO/AOO
control group. #p < 0.05 compared to AOO/
TDI.
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Fig. 4. Total levels of immunoglobulin (Ig) E,
IgG1 and IgG2a and IL-13. Serum IgE (a), BAL
IgE (d), serum IgG1 (b), serum IgG2a (c), and
serum IL-13 (e) were measured using ELISA.
Blood and BAL were collected 24 h after the
last intranasal challenge. Experimental groups
are identified by two abbreviations
(AOO=acetone olive oil; TDI= toluene-2,4-
diisocyanate); the first abbreviation indicates
the dermal treatment on days 1 and 8, whereas
the second abbreviation indicates the in-
tranasal instillations. n= 6–7 per group for
serum IgG2a, IgG1, IL-13 and BAL IgE, and
n=14–15 for serum IgE. Bars show the mean
and SD. *p < 0.05 and ***p < 0.001 com-
pared with the AOO/AOO control group.
###p < 0.001 compared to the AOO/TDI
treated group. ##p < 0.01 and
###p < 0.001 compared to AOO/TDI.
Fig. 5. Airway and tissue hyperreactivity.
Methacholine responsiveness was assessed 24 h
after the last intranasal challenge. The airway
reactivity to methacholine was measured using
a forced oscillation technique. Fig a and c show
the mean values of Rn and H, respectively. Fig
b and d, respectively, show individual values
and the groups mean of the area under the
curve (AUC) of Rn and H against methacholine
concentrations between 0 and 20mg/ml.
Experimental groups are identified by two ab-
breviations (AOO=acetone olive oil; TDI=
toluene-2,4-diisocyanate); the first abbrevia-
tion indicates the dermal treatment on days 1
and 8, whereas the second abbreviation in-
dicates the intranasal instillations. n=5–7 per
group. Graphs show the mean. *p < 0.05,
***p < 0.001 compared with the AOO/AOO
control group. #p < 0.05 and
###p < 0.001 compared to AOO/TDI treated
group.
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that after TDI uptake in the skin, the APC migrate to the local lymph
nodes and present TDI to the local T cells. Interestingly, the AOO/TDI
group also showed partly similar signs of systemic sensitization sug-
gesting that, next to the skin, the auricular lymph nodes also drain the
nasal mucosa. This was strengthened by the fact that DC, T- and B cells
were significantly increased in the ALN of both TDI treated groups.
When we investigated the different subpopulations in detail, a similar
significant increase of cytotoxic T cells, regulatory T cells, helper T
cells, B cells, CD11c+ and CD11b+ cDC, and an increasing trend of
moDC was found in the ALN of both TDI-treated groups, independently
of initial dermal TDI contact. As CD103+ and pDC both can induce T
regulatory cells that damp allergic immune responses, the decreasing
trend of both cells confirms the sensitization to TDI (van Helden and
Lambrecht, 2013). As we focused on the panel composition of DC in the
lung, we are aware that we might have missed some dermal DC sub-
populations in the TDI/TDI group (Malissen et al., 2014).
Sensitization is also shown by a significant increase of serum IgE in
both groups, confirming previous research (Matheson et al., 2005b; Ban
et al., 2006). Yet, in the TDI-dermally sensitized mice, the IgE serum
concentration was three times higher than the AOO/TDI treated group.
This suggests that contact of a sensitizer with two different exposure
sites, skin and airway mucosa, results in a much stronger immune re-
sponse compared to only TDI airway exposure.
An important immunological difference between AOO/TDI and
Fig. 6. Lung histology. H&E staining was performed on lung slices 24 after the last intranasal instillation. Alveolar widening (fig. 6a, 25x amplification), in-
flammation (fig. 6b, 200x amplification) and epithelial shedding (fig. 6c, 200x amplification) were scored on a semi-quantitative scale from 0 to 4, in a blinded
manner. The score for the epithelial shedding of the AOO/AOO group is zero. Experimental groups are identified by two abbreviations (AOO=acetone olive oil;
TDI= toluene-2,4-diisocyanate); the first abbreviation indicates the dermal treatment on days 1 and 8, whereas the second abbreviation indicates the intranasal
instillations. n= 6–7 per group. Bars show the mean with SD.
Table 1
Lymphocyte subpopulations in the lung.
T cells lung (%) AOO/AOO AOO/TDI TDI/TDI
CD3+ 9,09 ± 1,97 10,38 ± 1,76 10,77 ± 2,21
CD3CD4+ 5,9 ± 1,38 6,76 ± 1,30 6,83 ± 0,98
CD3CD4CD25+ 0.82 ± 0,37 1,12 ± 0,53 0,96 ± 0,22
CD3CD8+ 2,63 ± 0,66 3,12 ± 0,62 3,50 ± 0,96*
CD19+ 12,16 ± 3,59 9,69 ± 2,38 10,64 ± 3,42
Lung cells were stained with anti-CD3+ (T-lymphocytes), anti-CD3+CD4+ (Th-
lymphocytes), anti-CD3+CD4+CD25+ (activated/regulatory Th-lymphocytes)
and anti-CD3+CD8+ (Tc-lymphocytes) or stained with a single anti-CD19+ (B-
lymphocytes). Experimental groups are as described in Fig. 1. n= 12–14 per
group. The data is expressed as the mean with SD. *p < 0.05 compared with
the AOO/AOO control group.
L. Pollaris, et al. Toxicology 421 (2019) 84–92
90
TDI/TDI groups is illustrated by the cytokines production profiles of the
auricular and cervical lymph nodes. The AOO/TDI treated group
showed a mixed Th1/Th2 response; indicated by an increase of ex vivo
IFN-γ secretion and IL-13 concentration both in serum and ex vivo se-
cretion. Whereas, the TDI/TDI treated group had a similar Th1 re-
sponse, but a much more pronounced Th2 phenotype response, as
shown by a high ex vivo Th2 cytokine secretion (IL-4, IL-10 and IL-13),
along with high IL-13 serum levels. The pronounced Th2 response in
the fully TDI-treated group is also demonstrated by an increase of serum
IgG1, along with IgE and decrease of IG2a in the serum. Again, this
indicates that skin sensitization in combination with airway exposure
leads to a pronounced Th2 response. Previously, Ban et al., 2006
showed similar results when topical sensitization was followed by tra-
cheal instillation, leading to a Th2 type lung inflammatory response,
whereas sensitization via the airways was not effective (Ban et al.,
2006).
Yet, although both TDI treated groups (AOO/TDI and TDI/TDI)
showed pronounced sensitization, only the TDI/TDI treated group
showed AHR. The AHR was not accompanied by a neutrophilic, nor an
eosinophilic airway inflammation in BAL, and only very limited histo-
logical alteration in the blood vessels was found. An explanation could
be that the delivered volume/dose of TDI into the lungs was too limited.
To estimate the volume of the intranasal instillation, we based on
findings of Southam et al., who demonstrated that the instillation vo-
lume and anesthesia affect the distribution of substances in the lungs
(Southam et al., 2002). Therefore, we performed the instillation under
isoflurane anesthesia and increased the instillation volume to 40 μl. At
this volume, 40–60% of the substance is distributed to the lungs
(Southam et al., 2002). Yet, these distribution ranges are only demon-
strated for substances dissolved in aqueous solutions. As TDI is not
dissolvable in an aqueous solution we used the viscous vehicle acetone/
olive oil which will reduce substance distribution and volume that
reaches the lower airways (Ebino et al., 1999).
Our results suggest that the Th2 immune response, induced by the
combined skin and (upper) airway exposure, is necessary to induce
AHR. Probably, as we showed previously in an acute mouse model of
chemical-induced asthma, a complex interplay between neurogenic
mechanisms (TRPA1 and NK1 receptor), innate immune mechanisms
(mast cells) and adaptive immune mechanisms are involved in the in-
duction of airway hyperreacitivity (Devos et al., 2016). Notably, the
serum IgE levels of the TDI/TDI treated group were three times higher
compared to the AOO/TDI treated group, even five weeks after the
initial dermal sensitization phase. Moreover, the levels of total serum
IgE are 20 times higher than in our acute mouse model of chemical-
induced asthma (Devos et al., 2016; Pollaris et al., 2016). The literature
already showed a significant correlation between total serum IgE and
the presence of asthma and AHR. It is suggested that high levels of IgE
can induce ongoing mast cell activation, a cell shown to be crucial in
our chemical-induced asthma mouse model (Sears et al., 1991; Sunyer
et al., 1995; Devos et al., 2016; Virk et al., 2016). To further investigate
the presence of IgE in the lung, we measured IgE directly in the BAL
fluid. IgE was only significantly increased in TDI/TDI treated group,
which can explain the presence of AHR only in the TDI/TDI treated
group. Unfortunately, we could not prove that these IgE’s were TDI
specific as this is technically challenging (Wisnewski et al., 2011).
IL-13 has already been shown to play a key role for inducing AHR
(Hacha et al., 2012). Also, we found very high levels of the Th2 marker
IL-13 both in serum and ex vivo T cell secretion in the TDI/TDI treated
group, which might further explain the presence of AHR in this group.
Also, in the AOO/TDI group IL-13 was increased but to a significant
lesser extent. As the choice of mouse strain is known to have an impact
on the phenotypical outcome in asthma mouse models (De Vooght
et al., 2010), we used the Th2-proned BALB/c mouse strain. This mouse
strain is known to be more susceptible to reproduce asthmatic hall-
marks. Yet, despite this Th2 predisposition, we were unable to induce
lung inflammation, while the Th2 marker, IL-4, IL-13 and IgE were
highly upregulated.
All these experiments further confirm the importance of initial to-
pical exposure to chemicals on the airway response as also demon-
strated by our and other groups (Herrick et al., 2003; Vanoirbeek et al.,
2004, 2008; Ban et al., 2006; Wisnewski et al., 2011; Pauluhn and
Poole, 2011; De Vooght et al., 2013; Devos et al., 2016; Pollaris et al.,
2016).
An important novelty in our research is that we investigated whe-
ther DC, the most ‘professional’ APCs in the lung and responsible for
initiating an immune response and the induction of an asthmatic re-
sponse, still play a role in the effector phase 46 days after the initial TDI
contact (Provoost et al., 2010, 2012; Plantinga et al., 2013). As this is
still unstudied in isocyanate-induced asthma, we analyzed the different
DC and T cell subsets in the lung (Lambrecht and Hammad, 2003; Kopf
et al., 2015). No significant increase of DC was found in the lung after
long-term exposures to TDI. This could be because DC, after allergen
capture, migrate to the T cell area of the draining mediastinal lymph
nodes (MLN) within twelve hours via a CCR7 dependent manner
(Lambrecht and Hammad, 2003). Although there was no significant
increase of DC, there was a shift between the DC subpopulations, illu-
strated by a significant increase of moDC in the TDI/TDI treated group.
As they do not express CCR7, moDC do not migrate well to the draining
nodes leading to an accumulation into the lung (Lambrecht and
Hammad, 2014). As moDC have the capacity to initiate and maintain a
Th2 immune response it can explain the pronounced Th2 type sensiti-
zation in the TDI/TDI treated group (Plantinga et al., 2013). The ab-
sence of the increase of DC in the lung after a long-term exposure
protocol is however in contrast with other findings (Johnson et al.,
2004; Provoost et al., 2010, 2012; Plantinga et al., 2013). These dif-
ferences in DC response can be due to the different allergen exposure
(house dust mite and diesel exhaust particles) and different airway
exposure. Often an intratracheal aspiration technique is used, which
leads to a higher distribution to the lungs (80%) compared to the in-
tranasal instillation method (50–60%) (Foster et al., 2001; Southam
et al., 2002; Provoost et al., 2010; Plantinga et al., 2013). Along with
the instillation technique, the vehicle (aqueous vehicle), versus our
much more viscous vehicle (olive oil) influences the distribution in the
lungs (Ebino et al., 1999).
Our findings prove that repeated airway exposure to TDI causes
immunological alterations indicative of sensitization, but are not ac-
companied by physiological changes indicative of asthma (i.e. AHR).
However, the same type of airway exposure does lead to AHR if there
has been previous dermal contact with TDI. These results implicate that
Table 2
Leukocytes, macrophages and DC subpopulations in the lung.
Lung AOO/AOO AOO/TDI TDI/TDI
Leukocytes (# cells)
Leukocytes 294486±80507 345315±93944 374588±88273
Antigen presenting cells (%)
DC 5,04± 1,19 5,28±1,34 5,52±1,69
103+cDC 10,74± 2,12 12,31± 2,14 11,06± 1,44
CD11b+cDC 45,09± 3,59 44,49± 5,39 48,54± 5,01
moDC 43,96± 3,25 44,96± 5,46 49,48 ± 2,78*
pDC 8,65± 1,71 8,58±2,67 6,62±2,87
Macrophages 4,89± 0,81 4,83±1,36 5,11±0,59
Cells were analyzed using flow cytometry as CD45+ leukocytes, CD45+ low
auto fluorescent MHCII+CD11c+ DC (DC), CD45+ low auto fluorescent
MHCII+CD11c+CD11b−CD103+ cDC (CD103+ cDC), CD45+ low auto fluor-
escent MHCII+CD11c+CD11b+ CD103− conventional DC (CD11b+ cDC),
CD45+ low auto fluorescent MHCII+CD11c+CD11b+CD64+ monocyte derived
DC (moDC), and CD45+ low auto fluorescent MHCII+ CD11c+ SiglecH+
plasmacytoid DC (pDC). Macrophages were analyzed as auto fluorescent cells.
Experimental groups are as described in Fig. 1. n= 8 per group. The data is
expressed as the mean with SD. *p < 0.05 compared with the AOO/AOO
control group.
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long-term airway exposure to low TDI concentrations have a higher risk
of resulting in asthma if dermal exposure occurred earlier, again sug-
gesting that dermal protection is important to protect TDI-induced OA.
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